September 2026

AbbVie’s JUVMO (tavapadon) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease in adults. The once-daily oral medicine introduces a different approach to dopamine-based treatment by selectively targeting D1/D5 receptors.

AbbVie announced on September 28, 2026, that the FDA approved JUVMO tablets for adults with Parkinson’s disease. The company describes JUVMO as the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

Eli Lilly and Company has announced the launch of the Lilly Change the Course Commitment, a new global health initiative aimed at addressing gaps in access to diabetes and obesity treatments in low- and middle-income countries (LMICs). The company has set a goal of achieving parity in the number of patients treated with its diabetes and obesity medicines in resource-limited settings and high-income countries before 2040.